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dertaken to better understand the factors influencing the funding decisions.
RESULTS: During this period three submissions were considered under the RoR
criteria, two in 2008 and one in 2009. None of these were approved for listing on the
basis of the RoR, however two were accepted on the basis of high clinical need and
high but acceptable cost-effectiveness ratio. No submission has requested consid-
eration under the RoR, or been assessed under this criteria by the PBAC, since
November 2009. In comparison, from 2008-2011, 4 new applications and 5 re-sub-
missions requested listing on the LSDP and 3 of these were successful.
CONCLUSIONS: Despite stricter criteria for the LSDP than the RoR, applications to
the LSDP have had a better success rate. The RoR has not been used to justify a
listing on the PBS for at least four years, perhaps indicating that these criteria are
no longer favoured by the PBAC.
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OBJECTIVES: In Brazil, the concepts of minimization cost are being applied in price
analyses of newpharmaceuticals since 2004,whenwas published the Resolution of
Brazilian Chamber of Economic Regulation of Pharmaceuticals (CMED) n° 2/2004.
The drugs are divided in two types: new drugs presentations and new molecules,
these are classified by two categories: I - New product with patent of molecule,
which has scientific evidences of benefits over the medications used on the same
treatment; II - New products which were not classified as category I. The prices
analyses of new drugs are classified by twomethods the lowest international price
and cost of treatment considering an existing medication traded in Brazil. The
category I take in the consideration the lowest international price and the category
II considering the cost of treatment and international price, the lowest of them. The
goal of this research is to evaluate the price regulation of new molecules over the
last eight years and all the consequences in terms of prices and a decrease of costs
for the society. METHODS: Only data of prices analyses assessed by Office of Eco-
nomic Assessment of New Technologies of Brazilian Health Surveillance Agency
(Anvisa), which supports the decisions of CMED, were evaluated. RESULTS: Ac-
cording to our statistics, 209 new molecules - category I and II - (over 563 presen-
tations) were analyzed. During the last eight years, the difference between the
price proposed by the laboratories and the price analyzed by Anvisa has been
reduced, as demonstrated bellow: Category I 21%; Category II 39%. CONCLUSIONS:
It suggests the prices are more in conformity of the resolution. In fact, the Resolu-
tion CMED n° 2/2004 brought rational price decrease and, in consequence, cost
decrease for the private and public sector, improving the efficiency of health care.
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OBJECTIVES: Shortages of antibiotics adversely impact health outcomes and
health care costs. We assessed the prevalence of shortages of systemic antibiotics
and evaluated the characteristics of the antibiotics in short supply as reported by
federal agencies and private health care providers in the US on June 1, 2011.
METHODS: Data were collected from the FDA, American Society of Health-System
Pharmacists (ASHP), and Brigham and Women’s Hospital (BWH) websites. The
units of analysis were active ingredient(s) and route of administration. The preva-
lence of shortageswas estimated as a percentage of the total number of products in
theUSmarket as of June 1, 2011.RESULTS:A total of 18 antibiotic active ingredients
with 20 routes of administration were in short supply as of June 1st, 2011. The
prevalence of shortages of systemic antibiotics varied from20.6% reported byASHP
to 3.1% reported by the FDA and BWH. Injectable antibiotics had the highest (28.3%)
rate of shortage followed by oral products (11.4%). Three shortageswere resolved as
of December 31, 2011. The average duration of shortage as of Dec-31-2011 was
589.2304.6 days. The average number of companies marketing the products in
short supply was 5.43.1, with 5 products having only 1 manufacturer. Generic
products were available for 95.0% of the drugs. The brand name product was dis-
continued for 55.0% of the drugs. The drugs in shortage had an average of 2.31.0
shortages from 2001 to 2011. Shortages resulting from discontinuation occurred
because of problems with manufacturing (35.0%), raw materials (15.0%), FDA reg-
ulatory issues (5.0%), and for unknown reasons (45.0%). CONCLUSIONS: Over one-
fourth of the injectable systemic antibiotics available in the United States were
reported in short supply. Problems with manufacturing and raw materials repre-
sented most of the reported causes of shortages. Additional research is needed to
assess the risk factors and causes of pharmaceutical shortages in theUnited States.
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OBJECTIVES: To estimate the impact of Medicare Part D on prescription and med-
ical utilization among Arizona’s senior dual eligible population. METHODS: This
study was a retrospective analysis of changes in pharmaceutical utilization and
physician visits among Arizona senior dual eligible (Medicaid and Medicare) ben-
eficiaries between the ages of 66 and 80 as of January 1, 2006 relative to a compar-
ison group (Medicaid beneficiaries between the ages of 50 and 62 as of January 1,
2006). Medical and pharmacy claims from the Medicaid program from January 1,
2005 to December 31, 2007 were used in this analysis. Differences between groups
with respect to over-the-counter (OTC) medications, benzodiazepines, total pre-
scription utilization, generic medication utilization, and physician visits were es-
timated using generalized estimating equations. RESULTS: The dual eligibles and
comparison group were similar in their level and trend of utilization of over-the-
counter (OTC) medications and benzodiazepines in the pre-Part D period. Follow-
ing implementation of Part D, therewas an immediate decline in utilization of both
OTCmedications and benzodiazepines in the dual eligibles relative to the compar-
ison group (p 0.001). An upward trend was observed for both groups during the
pre-Part D period for total prescription utilization and generic medication utiliza-
tion. After the implementation of Medicare Part D, utilization of these drug classes
was significantly lower among the dual eligibles relative to the comparison group
(p0.001). Trends in physician office visits were similar for the entire study period.
During the first month of Part D, however, the dual eligibles had a significantly
larger increase in physician visits over the previous month relative to the compar-
ison group (p0.001). CONCLUSIONS: This study suggests that medication use for
dual eligible Medicare beneficiaries was disrupted by the transition of outpatient
drug benefits from Medicaid to Medicare Part D.
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OBJECTIVES: Between $69 billion and $230 billion is spent on health care fraud
annually. Most health care fraud cases are initiated by private citizens (qui tam
relators), who receive up to 30% of recoveries. We reviewed recently concluded
Federal health care fraud activities and compared our findings to those reported
previously Kesselheim. METHODS: Data were from Taxpayers against Fraud and
Department of Justice websites (January 2006 to October 2010). Cases pursued un-
der the Federal False Claims Act (FCA), the most commonly employed law invoked
in these investigations, were identified. Information on allegations, recoveries, and
qui tam relator awards was abstracted. RESULTS: From 2006 to 2010, 116 Federal
health care FCA cases were identified, mainly involving improper billing (64%),
improper financial relationships (34%), and illegalmarketing (18%) concluded.Most
cases involved pharmaceuticalmanufacturers (27%), hospitals (20%), or health sys-
tems (15%). In comparison to cases without qui tam relators (39 cases, $1.9 billion in
recoveries), those with qui tam relators (77 cases, $12.4 billion in recoveries) had
greatermean per-case recoveries ($380million versus $110million for pharmaceu-
tical cases; $42 million versus $25 million for hospital cases; and $170 million
versus $34 million for health systems cases). Qui tam relators received $1.1 billion.
Among qui tam relator cases closed since 2006 versus 1996-2005, cases involving
hospitals and health systems decreased 84% and 30%, respectively (per-case recov-
eries increased 14-fold and 2.7-fold, respectively); and pharmaceutical manufac-
turers’ cases tripled (to 34) (per-case recoveries doubled to $380 million).
CONCLUSIONS: Since 2006, 116 health care FCA cases were settled, accounting for
$14.3 billion in recoveries. Qui tam relators continue to play a dominant role, ac-
counting for the majority of 70% of the cases and financial recoveries. New inves-
tigation approaches including field audits, task force investigations, and predictive
modeling investigations augment qui tam relator led investigations.
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OBJECTIVES: High prices of orphan medicines are a cause for concern as they put
pressure on pharmaceutical budgets and may negatively influence patient access
to pharmacotherapy. While repurposing of drugs is an attractive strategy to over-
come the logistical and financial burden of the first phases of medicine develop-
ment, we argue that repurposed medicines for rare indications, for which effec-
tiveness evidence has already been published, do not warrant high prices.
METHODS:We identified 16 examples of repurposedmedicines for rare indications
for which effectiveness evidence was published prior to the application for orphan
designation and compared Belgian hospital prices between the common disease
and the rare indication of the same medicine. RESULTS: In the majority of cases
(n 13), the pharmaceutical form of the medicine was identical for the common
and for the rare indication. Medicine prices (per defined daily dose) for the rare
indication were nearly the same as for the common disease for cladribine and
tadalafil, and ranged from a two-fold difference (e.g. aztreonam, sildenafil) to a
200-fold difference for histamine. Three medicines had a different pharmaceu-
tical form for the rare indication: medicines for the rare indication were at least
56 times more expensive than for the common disease. Hospital prices per dose
for the rare indication were at least 23 times higher than for the common
disease. CONCLUSIONS: This study suggests that the majority of these selected
repurposed medicines for rare indications are over-priced. This pricing practice is
not justified and adds to the budget impact of treating rare diseases. There is a need
to individually assess repurposed medicines taking into account the costs of re-
search and development and the costs of market access that can be attributed to
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